{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-211080","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2024-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.008843+00:00","generated_at":"2026-05-31T06:51:41.874301+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IO Biotech Phase 3 trial IDMC recommends continuation; PFS endpoint expected H1 2025","bullets":["IDMC recommends Phase 3 trial of IO102-IO103 + pembrolizumab continue without modifications after interim analysis.","Interim ORR analysis did not meet pre-specified high statistical bar (p≤0.005); most alpha preserved for PFS.","Primary endpoint PFS event-driven at 226 events; trial 89% powered to detect 35% risk reduction; projected H1 2025.","No new safety signals observed; 407 patients enrolled across 100+ centers in US, EU, Australia, and elsewhere.","Phase 2 basket trial data for NSCLC and SCCHN accepted for presentations at ESMO and other fall meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-211080","json":"https://secwatch.observer/filing/0001193125-24-211080.json","markdown":"https://secwatch.observer/filing/0001193125-24-211080.md","text":"https://secwatch.observer/filing/0001193125-24-211080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524211080/0001193125-24-211080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312524211080/d889003d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:51:41.874301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}